Abstract: The present invention relates to combinations, pharmaceutical compositions and fusion molecules comprising an FGF21 (fibroblast growth factor 21) compound and a GLP-1R (glucagon-like peptide-1 receptor) agonist with optimized GLP-1R agonist/FGF21 compound activity ratio. It further relates to their use as medicaments, in particular for the treatment of obesity, being overweight, metabolic syndrome, diabetes mellitus, diabetic retinopathy, hyperglycemia, dyslipidemia, Non-Alcoholic SteatoHepatitis (NASH) and/or atherosclerosis.

Abstract: A process is provided for preparing compounds having the general formula I wherein R is a range of organic groups and X is a leaving group. The process comprises reacting a compound of formula II with a water-removing reagent. When X is halogen or a sulfonate, the compound of formula I may be prepared by reacting a compound of the formula III with a halogenating agent or a sulfonylating agent. Alternatively, when X is halogen, the compound of formula I can be prepared by reacting a compound of the formula IV where R2 and R2 are defined organic groups, with a compound of the formula halogen-C(—O)—O—C1-C8alkyl, halogen-C(—O)—O-aryl or halogen-C(—O)—O-benzyl.

Abstract: The present disclosure is directed to a process for the preparation of a compound having the formula: wherein R is unsubstituted or substituted C1-C12alkyl, unsubstituted or substituted C2-C4alkenyl, unsubstituted or substituted C2-C4alkynyl, unsubstituted or substituted C3-C6cycloalkyl, unsubstituted or substituted aryl, unsubstituted or substituted heteroaryl, or —SR1; R1 is unsubstituted or substituted C1-C12alkyl, unsubstituted or substituted C2-C4alkenyl, unsubstituted or substituted C2-C4alkynyl, unsubstituted or substituted cycloalkyl, unsubstituted or substituted aryl or unsubstituted or substituted heteroaryl; and X is a selected leaving group that is not halogen, and may specifically be methylsulfonate, trifluoromethylsulfonate, and p-toluenesulfonate. These compounds are valuable intermediates useful in the synthesis of compounds having pesticidal activity.

Abstract: A process for the preparation of a compound of formula I wherein R is a range of organic groups and X is a leaving group which process comprises a) reacting a compound of the formula II where R is defined for formula (I) with a water-removing reagent; or b) for the preparation of a compound of formula (I) wherein K is halogen or a sulfonate, reacting a compound of the formula III where R is defined for formula (I) with a halogenating agent or a sulfonylating agent; or c) for the preparation of a compound of formula (I) wherein X is halogen, reacting a compound of the formula IV where R is as defined for formula (I) and R2 and R3 are defined organic groups with a compound of the formula halogen-C(—O)—O—C1-C8alkyl, halogen-C(—O)—O-aryl or halogen-C(—O)—O-benzyl.

Abstract: The present disclosure is directed to a process for the preparation of a compound having the formula: wherein R is unsubstituted or substituted C1-C12alkyl, unsubstituted or substituted C2-C4alkenyl, unsubstituted or substituted C2-C4alkynyl, unsubstituted or substituted C3-C6cycloalkyl, unsubstituted or substituted aryl, unsubstituted or substituted heteroaryl, or —SR1; R1 is unsubstituted or substituted C1-C12alkyl, unsubstituted or substituted C2-C4alkenyl, unsubstituted or substituted C2-C4alkynyl, unsubstituted or substituted cycloalkyl, unsubstituted or substituted aryl or unsubstituted or substituted heteroaryl; and X is a selected leaving group that is not halogen, and may specifically be methylsulfonate, trifluoromethylsulfonate, and p-toluenesulfonate. These compounds are valuable intermediates useful in the synthesis of compounds having pesticidal activity.

Abstract: The present invention is directed to a process for preparing a compound having the formula: wherein R is a range of organic groups and X is a leaving group. The process may include reacting a compound of the formula with a water-removing reagent. Also, when X is a halogen, the process may include reacting a compound of the formula with a halogenating agent or a sulfonylating agent. Alternatively, when X is a halogen, the process may be carried out by reacting a compound of the formula IV where R2 and R3 are defined organic groups with a compound of the formula halogen-C(—O)—O—C1 -C8alkyl, halogen-C(—O)—O-aryl or halogen-C(—O)—O-benzyl.

Abstract: A process for the preparation of a compound of the formula and, where applicable, its E/Z-isomers, mixtures of E/Z-isomers and/or tautomers and acid addition products thereof, in each case in free form or in salt form, wherein: R is unsubstituted or substituted C1-C12alkyl, unsubstituted or substituted C2-C4alkenyl, unsubstituted or substituted C2-C4alkynyl, unsubstituted or substituted C3-C6cycloalkyl, unsubstituted or substituted aryl, unsubstituted or substituted heteroaryl, or —SR1; R1 is unsubstituted or substituted C1-C12alkyl, unsubstituted or substituted C2-C4alkenyl, unsubstituted or substituted C2-C4alkynyl, unsubstituted or substituted cycloalkyl, unsubstituted or substituted aryl or unsubstituted or substituted heteroaryl; and X is a leaving group; The process comprises reacting a compound of the formula: with a halogenating agent or a sulfonylating agent.

Abstract: Described is a process for the preparation of a compound of the formula wherein R is unsubstituted or substituted C1–C12alkyl, C2–C4alkenyl, C2–C4alkynyl, C3–C6cycloalkyl, aryl or heteroaryl, or —SR1; R1 is unsubstituted or substituted C1–C12alkyl, C2–C4alkenyl, C2–C4alkenyl, C2–C4alkynyl, cycloalkyl, aryl or heteroaryl; and X is a leaving group; which comprises a) reacting a compound of the formula wherein R is as defined for formula (I), with a water removing reagent.

Abstract: The present invention relates to an electrohydraulic brake system for motor vehicles which is controllable in a ‘brake-by-wire’ mode of operation by the vehicle operator as well as irrespective of the vehicle operator, is operated preferably in the brake-by-wire mode of operation, and can be operated in a fallback mode of operation in which only operation by the vehicle operator is possible.

Abstract: The invention relates to a medical probe for measuring radioactive radiation, comprising a housing that can be held single-handedly. A detector device (2) comprising a semiconductor diode is disposed in the housing and produces signals that interact with at least one of the following radioactive radiations: &agr;&bgr;+, &bgr;−and &ggr; radiation. A signal processing device (3) processes the signals produced by the detector device (2). A power supply device (4) provides the detector device (2) and the signal processing device (3) with power. The inventive probe is especially characterized in that a reproduction device (5) for reproducing the signals processed by means of the signal processing device (3) is mounted in the housing (1). The inventive device provides a compact measuring system that facilitates an (especially wireless) flexible intraoperative and extraoperative, local measurement of radioactively labeled tissue without requiring additional appliances.

Abstract: The invention relates to a process for the preparation of a compound of the formula wherein Q, Y, Z, R1, R2, R3, R4 and R5 are as defined in the specification, which comprises a) reacting a compound of the formula  with a halogenating agent to form a compound of the formula or b) converting a compound of formula (II) by means of a halogenating agent into a compound of the formula optionally c) converting the compound of formula (IV) into a compound of formula (III); d) converting a compound of formula (III) by means of a compound of the formula into a compound of the formula or e) converting a compound (IV) by means of a compound (V) into a compound (VI); and f) converting a compound (VI) by means of a chlorinating agent into a compound (I); a compound (IV); to a process for the preparation of a compound (III) and to a process for the preparation of a compound (IV).

Abstract: Described is a process for the preparation of a compound of the formula 1

Abstract: Described is a process for the preparation of a compound of formula (I) wherein R is unsubstituted or substituted C1-C12alkyl, C2-C4alkenyl, C2-C4alkynyl, C3-C6cycloalkyl, aryl or heteroaryl, or —SR1; R1 is unsubstituted or substituted C1-C12alkyl, C2-C4alkenyl, C2-C4alkynyl, cycloalkyl, aryl or heteroaryl; and X is a leaving group; which comprises: a) reacting a compound of formula (II) wherein R is as defined for formula (I), with a water-removing reagent; or b) for the preparation of a compound of formula (I) wherein X is halogen or a sulfonate, reacting a compound of the formula (III) wherein R is as defined for formula (I), with a halogenating or a sulfonylating agent; or c) for the preparation of a compound of formula (I) wherein X is halogen, reacting a compound of formula (IV) wherein R is as defined for formula (I); and wherein R2 and R3 are for example H, C1-C6alkyl, C3-C6cycloalkyl, phenyl or benzyl; with a compound of the formula halogen-C(═O)—O—C1-C8alkyl, halogen-C(═O

Abstract: The invention relates to a process for the preparation of a compound of the formula 1

Abstract: The Invention relates to a process for the preparation of a compound of the formula wherein Q, Y, Z, R1, R2, R3, R4 and R5 are as defined in the specification, which comprises a) reacting a compound of the formula  with a halogenating agent to form a compound of the formula b) converting a compound of formula (II) by means of a halogenating agent into a compound of the formula  optionally c) converting the compound of formula (IV) into a compound of formula (III); d) converting a compound of formula (III) by means of a compound of the formula e) converting a compound (IV) by means of a compound (V) into a compound (VI); and f) converting a compound (VI) by means of a chlorinating agent into a compound (I); a compound (IV); to a process for the preparation of a compound (III) and to a process for the preparation of a compound (IV).

Abstract: A method for the systemic control of blood-sucking parasites in warm-blooded animals or for the prevention of reinfestation, which comprises administering systemically to the warm-blooded animal a compound of formula 1

Abstract: The ink mixture contains at least one organosilane and optionally at least one hydrophobic silicic acid. The ink mixture can be used as a printing ink, especially as an ink for ink-jet printing.

Abstract: The invention relates to a process for preparing a compound of formula (I), in which X is CH or N, Y is NO2 or CN, Z is CHR3, O, NR3 or S, R1 and R2 are either each, independently of the other, hydrogen or unsubstituted or R4-substituted alkyl or together a two- or three-membered alkylene bridge or a two- or three-membered alkylene bridge in which one member is replaced by a hetero member selected from the group, consisting of NR5, O and S, R3 is H or unsubstituted or R4-substituted alkyl, R4 is an unsubstituted or substituted aryl or heteroaryl group, and R5 is H or alkyl, which comprises a) reacting a compound of formula (II) with a chlorinating agent or b1) initially reacting a compound of formula (IV) with a compound of formula (V) and b2) further reacting the compound of formula (II) obtainable thereby, with or without intermediate isolation, with a chlorinating agent, to intermediates used in this process, to the use of these intermediates and to a process for the preparation of these intermediates.

Abstract: This invention relates to a process for the production of a homogeneously waterproofed concrete (integrally waterproofed concrete) in which an aqueous hydrolysable, emulsion containing organosilicon compounds is added before curing to the fresh concrete mix prepared from water, inorganic and optionally organic constituents, which emulsion contains at least one alkoxysilane and optionally an organosilicon compound acting as a surfactant.

Abstract: The invention relates to a process for the preparation of a compound of the formula ##STR1## and, where applicable, its E/Z-isomers, mixtures of E/Z-isomers and/or tautomers, in each case in free form or in salt form, whereinQ is CH or N,Y is NO.sub.2 or CN,Z is CHR.sub.3, O, NR.sub.3 or S,R.sub.1 and R.sub.2 are either each independently of the other hydrogen or unsubstituted or R.sub.4 -substituted C.sub.1 -C.sub.8 alkyl, or together form an alkylene bridge having two or three carbon atoms, and said alkylene bridge may additionally contain a hetero atom selected from the group consisting of NR.sub.5, O and S,R.sub.3 is H or unsubstituted or R.sub.4 -substituted C.sub.1 -C.sub.12 alkyl,R.sub.4 is unsubstituted or substituted aryl or heteroaryl, andR.sub.5 is H or C.sub.1 -C.sub.